<SEC-DOCUMENT>0001178913-23-002424.txt : 20230712
<SEC-HEADER>0001178913-23-002424.hdr.sgml : 20230712
<ACCEPTANCE-DATETIME>20230712092329
ACCESSION NUMBER:		0001178913-23-002424
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230712
FILED AS OF DATE:		20230712
DATE AS OF CHANGE:		20230712

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PAINREFORM LTD.
		CENTRAL INDEX KEY:			0001801834
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39481
		FILM NUMBER:		231083395

	BUSINESS ADDRESS:	
		STREET 1:		65 YIGAL ALON ST.
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6744316
		BUSINESS PHONE:		972-3-7177051

	MAIL ADDRESS:	
		STREET 1:		65 YIGAL ALON ST.
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6744316
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2329964.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Washington, D.C. 20549</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">Form 6-K</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Report of Foreign Private Issuer</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Pursuant to Rule 13a-16 or 15d-16</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">of the Securities Exchange Act of 1934</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">For the month of July 2023</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">Commission File Number: 001-39481</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 18pt; font-weight: bold;">PainReform Ltd.</div>
    <div style="text-align: center; line-height: 1.25;">(Translation of registrant&#8217;s name into English)</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">65 Yigal Alon St., Tel Aviv 6744316</div>
    <div style="text-align: center; line-height: 1.25;">Israel</div>
    <div style="text-align: center; line-height: 1.25;">(Address of principal executive offices)</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">Form 20-F&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font>&#160;&#160;&#160;&#160;&#160; Form 40-F&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font>&#160;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">This Form 6-K, including the press release attached as Exhibit 99.1 hereto, is incorporated by reference into the Company&#8217;s Registration Statements on Form S-8 (Registration No. 333-257968 and
      333-265902) and the Company&#8217;s Registration Statements on Form F-3 (Registration No. 333-259318 and 333-254982).</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="text-align: justify; line-height: 1.25;"> On July 12, 2023, PainReform Ltd. issued a press release entitled &#8220;PainReform Announces Pricing of $2.7 Million Concurrent Registered
      Direct Offering and Private Placement.&#8221; A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.</div>
    <div style="text-align: justify; line-height: 1.25;"> </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">Exhibit Index</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z4ead5f2e306c4d649b02060e57ce10b3">

        <tr>
          <td style="width: 11.51%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Exhibit No.</div>
          </td>
          <td style="width: 1.23%; vertical-align: bottom;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 87.26%; vertical-align: bottom; border-bottom: #000000 2px solid;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Description</div>
          </td>
        </tr>
        <tr>
          <td style="width: 11.51%; vertical-align: bottom;">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><a href="exhibit_99-1.htm">99.1</a></div>
          </td>
          <td style="width: 1.23%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 87.26%; vertical-align: bottom;">
            <div style="text-align: justify; line-height: 1.25;"><a href="exhibit_99-1.htm">Press Release dated July 12, 2023</a></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="color: #000000; font-weight: normal; font-style: normal;">2</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <br>
    <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">SIGNATURES</font>&#160;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="z18e155fd72334f0faa2e3da37e7baadf">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">Date: July 12, 2023</div>
          </td>
          <td colspan="2" style="width: 50%; vertical-align: middle;">
            <div style="line-height: 1.25; font-weight: bold;">PAINREFORM LTD.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td colspan="2" style="width: 50%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: middle;">
            <div style="line-height: 1.25;">By:</div>
          </td>
          <td style="width: 46%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">/s/ Ilan Hadar</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 46%; vertical-align: top;">
            <div style="line-height: 1.25;">Ilan Hadar</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 46%; vertical-align: top;">
            <div style="line-height: 1.25;">Chief Executive Officer</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">
      <div style="text-align: center;"><font class="BRPFPageNumber" style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">3</font></div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <br>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 23.5.1.5152
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div style="text-align: right;"><u><font style="font-weight: bold;">Exhibit 99.1</font></u><br>
  </div>
  <div>
    <div class="BRPFPageHeader">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25;"><img width="175" height="80" src="image00001.jpg"></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PainReform Announces Pricing of
      $2.7 Million Concurrent Registered Direct Offering and Private Placement</div>
    <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">&#160;</font>&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">Tel Aviv, Israel &#8211; July 12, 2023 &#8211; </font><u>PainReform Ltd.</u> (Nasdaq: PRFX) ("<font style="font-weight: bold;">PainReform</font>" or the "<font style="font-weight: bold;">Company</font>"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it has
      entered into a definitive agreement for the purchase and sale of 301,230 of the Company&#8217;s ordinary shares (or pre-funded warrants in lieu thereof), at a purchase price of $9.00 per ordinary share, in a registered direct offering. In a concurrent
      private placement, the Company has agreed to issue in the offering unregistered warrants to purchase up to an aggregate of 301,230 ordinary shares. The offering is expected to close on or about July 14, 2023, subject to satisfaction of customary
      closing conditions.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Maxim Group LLC is acting as the exclusive placement agent for the offering.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The warrants will have an exercise price $9.00 per share, will become exercisable immediately upon issuance and have a term of five
      years from the date of issuance.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The gross proceeds from the offerings (without taking into account any proceeds from any future exercises of warrants), before deducting
      the placement agent's fees and other offering expenses payable by the Company, are expected to be approximately $2.7 million. The Company intends to use the net proceeds for funding research and development and clinical trials and for other working
      capital and general corporate purposes.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The ordinary shares (or pre-funded warrants) offered in the registered direct offering (but excluding the securities offered in the
      private placement) are being offered and sold by the Company pursuant to a &#8220;shelf&#8221; registration statement on Form F-3 (File No. 333-259318) originally filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on September 3, 2021 and
      declared effective by the SEC on September 13, 2021. The offering of the ordinary shares (or pre-funded warrants) to be issued in the registered direct offering is being made only by means of a prospectus, including a prospectus supplement, forming a
      part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the registered direct offering will be filed with the SEC. Electronic copies of the final prospectus supplement and the
      accompanying prospectus may be obtained, when available, on the SEC&#8217;s website at http://www.sec.gov or by contacting Maxim Group LLC, 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or
      telephone at (212) 895-3745.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;">The unregistered warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as
      amended (the &#8220;Act&#8221;), and Regulation D promulgated thereunder and, along with the ordinary shares underlying the warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the unregistered warrants and
      underlying ordinary shares may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these
      securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><font style="font-weight: bold;">About PainReform</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">PainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the
      Company's lead product, is based on the local anesthetic ropivacaine, targeting the postoperative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide
      localized and extended postoperative analgesia. The Company's proprietary extended-release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing
      the potential need for the use of opiates. For more information, please visit www.painreform.com.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Notice Regarding Forward-Looking Statements</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-style: italic;">This press release contains
        forward-looking statements about our expectations, beliefs and intentions</font>&#160;<font style="font-style: italic;">as well as statements relating to the concurrent registered direct offering and private placement, including, without limitation, as to the consummation of the offering described above, the expected proceeds from the offering,
        the intended use of proceeds and the timing of the closing of the offering. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek",
        "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking
        statements are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking
        statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not
        guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in
        forward- looking statements, including, but not limited to, the following: our ability to continue as a going concern, our history of losses, our need to raise additional capital and our ability to obtain additional capital on acceptable terms, or
        at all; our dependence on the success of our initial product candidate, PRF-110; the outcomes of preclinical studies, clinical trials and other research regarding PRF-110 and future product candidates;&#160; the impact of the COVID-19 pandemic on our
        operations; our limited experience managing clinical trials; our ability to retain key personnel and recruit additional employees; our reliance on third parties for the conduct of clinical trials, product manufacturing and development; the impact
        of competition and new technologies; our ability to comply with regulatory requirements relating to the development and marketing of our product candidates; our ability to establish and maintain strategic partnerships and other corporate
        collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights and our ability to operate our
        business without infringing the intellectual property rights of others; the overall global economic environment; our ability to develop an active trading market for our ordinary shares and whether the market price of our ordinary shares is
        volatile; and statements as to the impact of the political and security situation in Israel on our business. More detailed information about the risks and uncertainties affecting us is contained under the heading "Risk Factors" included in the
        Company's most recent Annual Report on Form 20-F and in other filings that we have made and may make with the Securities and Exchange Commission in the future.</font></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Contact:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Crescendo Communications, LLC</div>
    <div style="text-align: justify; line-height: 1.25;">Tel: 212-671-1021</div>
    <div style="text-align: justify; line-height: 1.25;">Email: <u>prfx@crescendo-ir.com</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Ilan Hadar</div>
    <div style="text-align: justify; line-height: 1.25;">Chief Executive Officer</div>
    <div style="text-align: justify; line-height: 1.25;">PainReform Ltd.</div>
    <div style="text-align: justify; line-height: 1.25;">Tel: +972-54-5331725</div>
    <div style="text-align: justify; line-height: 1.25;">Email: <u>ihadar@painreform.com</u></div>
    <div style="line-height: 1.25">&#160;
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !0 *\# 2(  A$! Q$!_\0
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MHHH KW__ "#[G_KDW\C7&^"M8T[3?#;+>7<43^<S;"?F(P.W6NROO^0?<_\
M7)OY&N9^'J(WALEE4L)VY(Y' KHA;V4K]T>9B.;Z[3Y'KRRW^7H0>&[.XO/$
ME_X@:WDAMGW"%77#/G'./H/UJY87.MZU975Z+A].9'988&@!&!W8MR?PQ5B\
MUEIM2O+:UR;;3(O-O'7JSXW+$#ZXY/L0.]4M(+Z]H\FK:O>DPG?BV1_+BC _
MO8Y/XFK;;]Z2[>9DJ<:35&$FV^9O6U^[NMK=E<OZ#JMYK_AYIE:.WO58QEPF
MY=P/7'O4/AG5-2U&75;>]FB:2UD$2-&F #\PS[]*K_#W']@2D=#<O_2CP?QJ
MWB$?]/?]6I3C%<Z2V_S"A5J3^KR<G[R=]=]&1V>J>()-?O=(,UM*\48(F,>U
M4SCYB.I//3-30:EJ^F>)[?2]2N8[N&Z0F.58@A4CV'T_6FZ7_P E%UC_ *X)
M_2DUO_D?="_W&_K5:.7+9;?H9ISC3]IS.ZG;?IS6MY_,I_%SGP#< =3-'_.F
M6_CC2+3PK965G-]MU1K5(8;.%26>3;@#G@#/>G?%W_D0;C_KM'_.H]8\)CQ)
MX#TN6UPFJ6EK');2J<$G:#MS[]O0XJZ?(Z,54VN_T.ZISJK)PWL6OAKX6O/#
M6B3G4-JW5W(':)3GRP!@#([]:TH-1O=>U&[BL+D6EC:/Y33! SROWQG@ 51\
M ^+QXDTLVUXPCU:U^2XC;@MCC>!^'/H1]*H^%=.L)+_4]-U&(F\AF+*#(REE
M]L$9_P#KU,U)SG*INC"I.WLJ=+X7?K;9;71L66J:D^IW^A3W$7VV)/,M[KR^
M&4XZKZ\UD:1;ZJ_BG6D@OX([E=GFRM!D/Z8&>*Z2WL=$T[6HHK>!5OWC8@@L
MQ"#KDDG ^M9GA_\ Y';Q#]4J5)6DXKIV\S*=*3G2C4E=\S6C>BLW;IKY[EJY
MU>\N];.C:?+'$8(]]W=LH.WIPH/&>>_]*YY[B-/$.E^(;YYKVS!>TMI9D5#&
M2<>: ."#S@]<5>L+94\<:Q8WG"WB"1!G'F+G) ]NN?I4OCM5GM--TNW4>?-<
M 1QKV &,X]!FJCRJ2@NJ_34F<ZCH3K-^]%NR]'9*VWZZDEUJ>NVGBF#3DEMK
MF.X1I(P4V8'/WC[8SQUJWIC>(WN=2MKYXU5 !;7/E  GV4'D?6JEZNWXA:.I
M/2U8?HU=;652225DM5^ITX:G*I.;<W[LFK7Z67^9QVE:GXAU&]U+3_/MA);2
M!#<>7\J=>B]R??@4MIJVO0Z[<:',UO<W!3?%<,NP*OJ0.OT]:D\*_P#(Q>(_
M^OD?S-,7_DJ#_P#7F*T?+S25EM?\CE@ZGLJ<^=W<K;]+M?T]QQU+6='\1V5E
MJ%U%>6U[\JLL00HWX?YYKK:Y#Q0/^*J\._\ 78_TKKZQJVM&7<[\(Y*=2FVV
MD]+Z]$RIJ&FVNJ0K#=HSQ@YVARH/;G!YK$U&PTGPII5YK-K;&.2VB9E42-M9
ML8 (S@\D5TU<U\0+62[\#:I'$"76,/@=PI!/Z T4FW)0;T;-:]*G9U.5<R6]
MM2C\,8S)X-%W.?,GO;B:>=FYWL6(.?RK9M_">C6UP9H[7&6W>678H#Z[<XKC
M_A+K\$NER:)*X6>%FEA!/WT8Y./<'^=>E5IB>>%:2VN9X>%*M1A*23M^?4R8
M/#>EVT]Q+! T37"E7"2,!@]<#/'X46?AO2K"Y%Q:VQBE (+"1N<C!SSS6M16
M'M)]S98:BK-06GD8T/A71X+A+B.V99D8,)/-;<3[G/-+<^%])N[E[F>V9YG;
M=O,K9!]N>/PK8HH]I.][B^JT+<O(K>B,'4_!NAZS<+/J-HUPZ($4/,^T =.,
MXS[]:M:-X?TW0(Y(]-A>&.3&4,K,HQZ DX_"M2BAU)N/*WH:JG!.Z6ISEWX%
M\.7NI2:C)IX6\D?>TT4KHV[U^4CK5_4/#VF:I(DMS;YF0865&*N!]15V[O+:
MQMVN+NXB@A499Y'"@?B:P(O$]QKCF/PY9F>'.&U"Y4I /]T?>D/TP/>KBZLM
M;O0SJ0HVY9)._2QIV^EZ;I5M)'$GEB?Y7<N2[G_>ZFJ\'A71X9$GBM7CE!#;
MQ*VX]^3GG\:N6.F"U;S[B=[J[8?--)V]E X4>P_6K]2YR3T8OJ])I<T%IMHM
M"EJ.DV6J*@NHLO&<QR*Q5T/L1R*BL=#L;"Y-RB/+<D;?/G<R/CT!/0?2M*BI
MYY6M?0MT:;GSN*OW,:;PMI%Q<-<36S-,S;O,,K;@?8YX_"M-K6-K/[*=WE;-
MGWCG&,=>M344.<GNPC0I0ORQ2OOH9%IX:TJPNEN;:V,<RG.X2-S]>>?QIH\*
MZ.+C[0+9O/#;O-\UMV?KFMFBG[2?<GZK0M;D7W(R+OPSI5]=/<W-NTDS'.XR
M-Q].>/PK4AB6"%(DSM10JY.3@>]/HI.4FK-EPI4X-RC%)L*1E5T9&4,K#!!'
M!%+14FAX;XN\$ZAX7U!M2TH3-IX?S(I8<[[8^AQSCT/IUK7\/_%R2*)(=<MC
M.!Q]JM@,G_>7U^GY5ZV0",$9!KF-5^'_ (<U=VEDL1!,W62V/ED_EP?RKT(X
MNG4BHUXW\^IYLL'4I2<\/*U^CV)+'QYX9OU7RM6@1C_!,?+(_.M=-6TV0934
M+1AZB93_ %KSZY^#=DY/V?5KA!V$L2OC^55?^%+C/_(;'_@+_P#95+I85[3:
M^1:JXQ;TT_F>EOJVFQC+ZA:*/]J91_6LVY\:^&K3/FZS:9'9'WG],UQL'P8L
M@1Y^KSN.XCB5?YYK:LOA7X8M2#)!/=,/^>TIQ^0P*APPR^TWZ(M3Q4OL)>K*
M]W\6M"1_*L(+R_F)PJQ18!/X\_I3(]6\?>(QBQTRWT2U;_EO=_-)CV7_ .M7
M9V&C:;I:;;&PM[<?],XP#^=7JEU:4?@A]^O_  "U2JR^.?W:'(6'@"R%PM[K
MMW<:W>J<AKMLQ(?]F/I^==<JJBA54*JC  & !2T5C.I*?Q,VA",/A04445!8
24444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
